Introduction: Increased distance between the base of the nose and lip's vermilion is difficult to treat, and often there are restrictions for the use of botulinum toxin and cutaneous fillers.
Objective: To describe a new technique for the treatment of the upper lip ptosis.
Methods: A prospective pilot study was conducted with 15 female patients bearing increased distance between the base of the nose and the labial cutaneous-mucosal transition line. Five weekly sessions of intraoral non-ablative 2,940nm Er:YAG laser were performed. For the evaluation of outcomes, standardized records were performed with a 3D photographic camera, and comparative measurements of the philtrum's height and the nasolabial angle were taken before and after the treatment.
Results: There was a shortening ranging from 2 to 4 mm in the philtrum's measurements, and a decrease in the nasolabial angle, in addition to increased firmness of the skin in the upper lip.
Conclusion: Intraoral non-ablative 2,940nm Er:YAG laser can be a therapeutic option for the treatment of upper lip ptosis.

Keywords: AGING; LASERS; LIP

Systemic sclerosis is a disease of unknown cause, is a rare pathology that, when not treated in time, produces severe damage to the facial aesthetic anatomy causing a significant impact on the quality of life. The case of a 54-year-old woman, with a history of systemic sclerosis of 25 years of evolution, and who was stable from her disease over four years ago. The patient consults for resolution of her facial deformity, which is why she proceeds to perform minimally invasive low-risk procedures such as transcutaneous blepharoplasty and fillings with hyaluronic acid obtaining aesthetically adequate results.

Keywords: Blepharoplasty; Hyaluronic acid; Scleroderma, diffuse

INTRODUCTION: Facial erythema is a frequent and often distressing complaint in patients with rosacea. Botulinum toxin has been proposed as a treatment of facial erythema with relatively good results.
OBJECTIVE: This study aims to assess botulinum toxin’s safety and efficacy in a split-face trial in two different administration modalities: intradermal injections on one side of the face and facial electroporation on the other side.
MATERIALS AND METHODS: The trial enrolled 20 subjects aged between 25 and 75 years with erythematotelangiectatic rosacea. Subjects received five units of Botulinum toxin through intradermal injections on the right side of the face. The same amount was introduced through electroporation technique on the left side. We conducted the evaluation using a standardized erythema grading system (System Vectra) and digital photographs at baseline, 2, 6, and 12 weeks.
RESULTS: The effectiveness in reducing the erythema of botulinum toxin with both the injection and electroporation was evident from the second week and persisted until week 12. Both techniques were effective.
CONCLUSIONS: Intradermal injection of botulinum toxin and electroporation seems both effective and safe for treating erythema related to rosacea. The mechanism of action is still controversial.

Keywords: Erythema; Mesotherapy; Botulinum Toxins, Type A